Citius announces pre-ind submission to fda for a novel stem cell therapy for ards in covid-19

Citius announces pre-ind submission to fda under the coronavirus treatment acceleration program for a novel stem cell therapy for acute respiratory distress syndrome (ards) in covid-19.citius pharmaceuticals inc - company's goal to initiate clinical trial in patients in 2020.

CTXR Ratings Summary

CTXR Quant Ranking